Lombard downgrades sales, downplays Biocompatibles link
This article was originally published in Clinica
Executive Summary
London AIM-quoted device company Lombard Medical says that its sales for 2002 will be off target by £500,000 ($785,000) and that the pre-tax loss for the year will reach £13.3m. The company blames slower than expected rollout of the Aorfix AAA reinforced graft devices from its Anson subsidiary.